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ABSTRACT DDT, MF-2 cells, which are derived from
hamster vas deferens smooth muscle, contain a1-adrenergic
receptors (54,800 ± 2700 sites per cell) that are coupled to
stimulation of inositol phospholipid metabolism. Incubation of
these cells with tumor-promoting phorbol esters, which stim-
ulate calcium- and phospholipid-dependent protein kinase,
leads to a marked attenuation of the ability of a,-receptor
agonists such as norepinephrine to stimulate the turnover of
inositol phospholipids. This turnover was measured by deter-
mining the 32p content of phosphatidylinositol and phos-
phatidic acid after prelabeling of the cellular ATP pool with
32p;. These phorbol ester-treated cells also displayed a decrease
in binding affinity of cellular al receptors for agonists with no
change in antagonist affinity. By using affinity chromatogra-
phy on the affinity resin Affi-Gel-A55414, the a, receptors were
purified =300-fold from control and phorbol ester-treated
32P1-prelabeled cells. As assessed by NaDodSO4/polyacryl-
amide gel electrophoresis, the Mr 80,000 a,-receptor ligand-
binding subunit is a phosphopeptide containing 1.2 mol of
phosphate per mol of a, receptor. After phorbol ester treat-
ment this increased to 3.6 mol of phosphate per mol of a,
receptor. The effect of phorbol esters on norepinephrine-
stimulated inositol phospholipid turnover and a,-receptor
phosphorylation showed the same rapid time course with a
til2 < 2 min. These results indicate that calcium- and phospho-
lipid-dependent protein kinase may play an important role in
regulating the function of receptors that are coupled to the
inositol phospholipid cycle by phosphorylating and deactivat-
ing them.
The mechanisms whereby hormones regulate cellular metab-
olism are of great current biochemical interest. In addition to
the well-delineated, second messenger-generating adenylate
cyclase system, another potentially quite general pathway
has been demonstrated recently. This pathway involves
receptor-mediated stimulation of the breakdown of mem-
brane polyphosphoinositides (phosphatidylinositol phos-
phates) to diacylglycerol and inositol trisphosphate (1-5).
Both products are potential second messengers serving to
stimulate calcium- and phospholipid-dependent protein
kinase (protein kinase C) (6, 7) and to mobilize intracellular
calcium (8, 9), respectively. Factors known to stimulate this
pathway include agonists such as acetylcholine (10), angio-
tensin (11), and catecholamines acting via a1-adrenergic
receptors (1, 12-16).
A powerful approach to the study of this signal transfer
pathway has been the use of the tumor-promoting phorbol
esters, which appear to mimic endogenously produced
diacylglycerol in activating protein kinase C (17, 18), thus
bypassing the receptor signal. By using this approach it has
been demonstrated recently that receptors for epidermal
growth factor (19, 20), insulin (21, 22), and somatomedin C
(21) are either directly or indirectly phosphorylated by
protein kinase C. Although in a few of these systems receptor
phosphorylation has been shown to correlate with alterations
in ligand binding (23-26), almost nothing is known about the
possible relationship of these phosphorylation events to
alterations in physiological responsiveness. Moreover, the
biochemical signal transfer pathways for these receptors
have not yet been clearly elucidated. The adenylate cyclase-
coupled ,3-adrenergic receptors have also been shown to be
a target of protein kinase C-mediated phosphorylation (27,
28). This covalent modification of the f3 receptor appears to
uncouple it from adenylate cyclase stimulation, thus leading
to "desensitization" of the receptor response.
Protein kinase C is presumably activated subsequent to the
stimulation of receptors that lead to the breakdown of
polyphosphoinositides. Thus, agonist-promoted protein
kinase C-mediated phosphorylation of such receptors might
serve as a mechanism for feedback regulation of the functions
of those receptors. In the present studies we sought to test
whether the activation of protein kinase C by phorbol esters
leads to alterations of a1-adrenergic receptor function. Our
results indicate a striking phorbol ester-induced uncoupling
of a1-receptor-mediated stimulation of phosphatidylinositol
(PtdIns) turnover paralleled by phosphorylation of the a,-
adrenergic receptor protein in cultured DDT1 MF-2 smooth
muscle cells.
MATERIALS AND METHODS
A55414 {4-amino-6,7-dimethoxy-2[4'-(4"-aminobenzyl)1-
piperazinyliquinazoline; see also Fig. 3}, a prazosin analogue
and a potent a1-adrenergic antagonist, was prepared at
Abbott Laboratories, and its synthesis and biological activity
will be described separately.
Cell Growth and Labeling. DDT1 MF-2 cells were grown in
3-liter suspension cultures as described by Cornett and
Norris (30). Cells (109) were then incubated in phosphate-free
Dulbecco's modified Eagle's medium (DMEM) with 6 mCi (1
Ci = 37 GBq) of 32P, in a total volume of 60 ml for 1 hr at 37°C.
Aliquots of cells were incubated for various lengths of times
with or without phorbol esters as indicated in the figure
legends. Incubations were terminated by diluting with 3 vol
Abbreviations: HEAT, 2-[3-(4-hydroxyphenyl)ethylaminoethyl]tet-
ralone; NE, norepinephrine; Ptdlns-P, phosphatidylinositol-4-phos-
phate; PtdIns-P2, phosphatidylinositol-4,5-bisphosphate; Ptdlns,
phosphatidylinositol; PtdOH, phosphatidic acid; DMF, dimethylfor-
mamide; EDAC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;
PMA, 4,3-phorbol 12f3-myristate 13a-acetate; aPDD, 4a-phorbol
12,8,13p-didecanoate; BPDD, 4f3-phorbol 12,8,13a-didecanoate;['25I]APDQ, 4-amino-6,7-dimethoxy-2-{4-[5-(4-azido-3-[1251]iodo-
phenyl)pentanoyl]-1-piperazinyl}quinazoline.
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of ice-cold buffer (50 mM Tris HCl/10 mM NaF, pH 7.4) and
centrifugation. The cells were washed once in the same
buffer.
Labeling of Phospholipids. Cells were washed with phos-
phate-free DMEM and incubated in the same buffer contain-
ing 32p; (20 ,uCi/ml) for 1 hr at 370C. Cells were washed and
treated with or without phorbol esters. The cells were then
incubated in the absence or presence of 10 ,M norepineph-
rine (NE) at 37TC in a total volume of 0.9 ml (3 x 106 cells).
In the first series of experiments (Fig. 1), cells were washed
once with ice-cold buffer after treatment with phorbol esters
and were further stimulated with 10 AM NE for 10 min. The
same results were obtained when NE was coincubated with
the phorbol esters. In the second series of experiments (Fig.
5), in which the effects of short-time phorbol ester treatment
were investigated, cells were stimulated with 10 AM NE for
1 min following phorbol ester treatment. At 1 min of NE
stimulation, phosphatidic acid (PtdOH) 32p labeling was the
most convenient parameter to follow. Phospholipid 32p la-
beling was stable up to 20 min after 32Pi removal. Incubation
with NE was terminated with 2 ml of ice-cold methanol/HCl
(100:1) and phospholipids were extracted according to
Agranoff et al. (31) and measured according to Jolles et al.
(32). The migration of the labeled phospholipids was verified
with authentic phospholipids visualized with iodine vapor.
Following thin-layer chromatography and autoradiography,
the bands were cut and the 32p was quantitated.
Membrane and Receptor Purification. Whole cells (109)
were lysed by resuspension in hypotonic buffer (5 mM
Tris HCl/10 mM NaF/5 mM EDTA, pH 7.4) and membranes
were pelleted at 45,000 x g for 20 min. The pellet was
resuspended in 10 ml of buffer (50 mM Tris HCl/10 mM NaF,
pH 7.4) and sonicated by six 5-sec bursts with 1 min between
the bursts at 4°C. The membrane suspension was'diluted to
40 ml and centrifuged at 600 x g for 10 min. This supernatant
was centrifuged at 45,000 x g for 15 min. The pellet was
washed twice in the same buffer. The membranes were then
solubilized by sonication for 90 sec with 3.5 ml of 1%
digitonin in 50 mM Tris'HCI/48% glycerol/150 mM NaCl/5
mM EDTA, pH 7.4, including leupeptin (10 ,tg/ml), soybean
trypsin inhibitor (10 ,ug/ml), and bacitracin (200 ,ug/ml). The
resulting suspension was diluted 1:2 with the above buffer
lacking digitonin and glycerol and was centrifuged at 45,000
x g for 90 min. The supernatant was frozen in liquid N2 and
stored at -70°C. The soluble extract (7 ml) was thawed and
applied to 9 ml of Affi-Gel-A55414 (see below) preequili-
brated with 3 column vol of 50mM Tris HCI/150 mM NaCI/5
mM EDTA/10 mM NaF/0.05% digitonin/24% glycerol, pH
7.4, including the above protease inhibitors. After entering
the resin, the soluble extract was allowed to equilibrate with
the resin for 30 min at 25°C and then for 15 min at 4°C. The
resin was then washed with 3 column vol of ice-cold equili-
bration buffer lacking glycerol but including 300 mM NaCl.
After the temperature of the resin returned to 25°C ('15 min),
the a1 receptor was eluted with 3 column vol of the same
buffer but including 200,M phentolamine. The phentolamine
eluate was then concentrated to -1 ml on an Amicon
Centriflo ultrafiltration membrane'cone by centrifugation at
600 x g. The concentrate was then desalted on a Sephadex
G-50 column (0.5 x 12 cm). An aliquot of the eluate was used
for determination of the receptor number by 125I-labeled
2-[3-(4-hydroxyphenyl)ethylaminoethyl]tetralone (125I_
HEAT) binding and the rest was lyophilized to dryness and
redissolved in 0.1 ml of NaDodSO4/PAGE sample buffer.
Proteins were measured by the method of Lowry et al. (33)
and the amido schwartz method of ref. 34.
Radioligand Binding Assays. Soluble binding assays were
performed by incubating 50 gl of receptor preparation with a
saturating concentration of 125I-HEAT (29) (1.5-2 nM) in 50
mM Tris HCI/150mM NaCl/5 mM EDTA/0.05% digitonin in
a volume of 100 ,4 for 60 min at 250C. Nonspecific binding
was assessed in the presence of 10 jiM prazosin. After
incubation, bound 125I-HEAT was separated from free 12511
HEAT by Sephadex G-50 chromatography. Whole cell re-
ceptor binding assays were performed by incubating cells
with 125I-HEAT with and without competitor in phosphate-
buffered saline including 0.1% bovine serum albumin in a
volume of 0.4 ml for 30 min at 370C. The assays were
terminated with ice-cold buffer and were filtered on Whatman
GF/C filters and filters washed with an additional 20 ml of
buffer. Binding data were analyzed by nonlinear least-
squares computer curve fitting and the significance of differ-
ences between fitted parameters was tested as described (35).
Photoaffinity Labeling. Photoaffinity labeling of purified
plasma membranes was performed as described (36). Purified
a,-receptor preparations were photoaffinity labeled by incu-
bation with 1 nM 4-amino-6,7-dimethoxy-2-{4-[5-(4-azido-3-
[1251]iodophenyl)pentanoyl]-1-piperazinyl}quinazoline
([125I]APDQ) in a volume of 0.5 ml overnight at 40C. The
mixture was desalted on Sephadex G-50 columns (0.5 x 12
cm) into 5 mM Tris HCl/0.05% digitonin, pH 6.8. The eluate
was irradiated for 90 sec (36). The photolyzed preparation
was lyophilized and then dissolved in 0.1 ml of NaDodSO4/
PAGE sample buffer.
NaDodSO4/PAGE. Gel electrophoresis was performed ac-
cording to the method of Laemmli (37) with 10% slab gels.
Gels were dried and autoradiographed at -80°C with Kodak
XAR-5 films and intensifying screens. After autoradiographic
visualization the gel was sliced and rehydrated and the 32P
was quantitated by liquid scintillation spectroscopy.
Preparation of Affi-GeI-A55414. Affi-Gel 202 (a suc-
cinylaminoalkyl derivative of crosslinked Bio-Gel A) was
incubated with A55414 by using a ratio of 120 g (1.86 mmol
of succinylaminoalkyl groups) ofwet gel cake to 240 mg (0.48
mmol) of A55414 in 120 ml of 50% dimethylformamide
(DMF)/H20, pH 4.5, in the presence of 1-ethyl-3-(3-dimeth-
ylaminopropyl)carbodiimide (EDAC) (2.4 mmol). The same
amount of EDAC was added again after 5 min and after 70
min. After 18 hr of incubation at 22°C the gel was allowed to
react for an additional 2 hr with glycine (2.4 mmol) and EDAC
(2.4 mmol) to block any unreacted succinylaminoalkyl
groups. The gel was then washed extensively with 1 liter of
50% DMF/H20, 2 liters of H20, 1 liter of 6M guanidine HCl,
12 liters of H20, and 4 liters of 25 mM Tris HCl (pH 7.4).
ATP Determination. The specific activity of the labeled
ATP was determined as described (38) and was found to be
0.18 Ci/mmol. There was no change in the specific activity of
the ATP after phorbol ester treatment under the conditions of
the experiments.
RESULTS
One of the early cellular events resulting from agonist
occupancy of a1 receptors is a breakdown of membrane
polyphosphoinositides [phosphatidylinositol-4-phosphate
(PtdIns-P); phosphatidylinositol-4,5-bisphosphate (PtdIns-
P2)] to diacylglycerol and inositol trisphosphate (1-5). Be-
cause of rapid receptor-mediated metabolism, this process
can be efficiently followed in cells in which the intracellular
ATP pool is labeled by 32P by monitoring the resynthesis of
PtdIns and PtdOH. As shown in Fig. 1, incubation 4fDDT1
MF-2 cells preequilibrated with 32P, with the a,-receptor
agonist NE at 10 ,M resulted in a significant increase (mean
+ SEM; n = 3) in 32p labeling ofboth PtdIns (34% + 10%) and
PtdOH (121% + 12%). A small but significant increase in the
32p labeling of PtdIns-P and PtdIns-P2 (10% ± 5%) also
occurred, whereas the labeling of the other phospholipids
was not altered. This stimulation by NE was completely
blocked by 1 gM prazosin, indicating that the NE effect is
a1-adrenergic in nature (data not shown).
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Fic. 1. NE stimulation of phospholipid 32p labeling in control and
phorbol ester-treated DDT1 MF-2 cells. Cells were incubated with
32P, for 60 min, washed, and then treated with phorbol ester for 10
min. Ptdlns-P and PtdIns-P2, clear bars; Ptdlns, hatched bars;
PtdOH, filled bars. The results represent the NE-stimulated increase
in phospholipid 32p labeling expressed as the percent of the labeling
observed in the absence of NE (basal). Results are mean ± SEM of
at least three experiments performed in triplicate. Under basal
conditions Ptdlns-P and PtdIns-P2 = 14,565 ± 2883 cpm per assay,
Ptdlns-6868 + 1244 cpm per assay, and PtdOH = 3571 + 524 cpm per
assay (mean ± SEM) for control cells. Phorbol ester treatment for up
to 10 min did not alter these numbers significantly. Different from
control by two-tailed paired Student's t test: ***, P < 0.001; **, P <
0.01; *, P < 0.05.
Preincubation of cells with active phorbol esters for 10 min
resulted in a drastic attenuation of the NE-promoted stimu-
lation of PtdIns and PtdOH labeling. Fig. 1 shows that this
attenuation occurred after preincubation with 0.1 ,M 4f-
phorbol 12f3-myristate 13a-acetate (PMA) or with 1 ,M
4,-phorbol 12,B,13a-didecanoate (,3PDD). By contrast, the
nontumor-promoting 4a-phorbol 12,B,13a-didecanoate
(aPDD) had no effect.
Intact DDT1 MF-2 cells in suspension culture and at a
density of -300,000 cells per ml contain 54,800 ± 2700 (mean
± SEM; n = 8) a1 receptors per cell, as determined by
specific 1251-HEAT binding. Incubation of intact cells with
tumor-promoting phorbol esters for 10 min resulted in no
apparent change in the total number of a1 receptors per cell
or antagonist affinity for the antagonist 125I-HEAT (Fig. 2
Upper). On the other hand, the potency of the agonist NE in
competition for 125I-HEAT binding was reduced, as shown in
Fig. 2 Lower (see Fig. 2 Lower legend for EC50 and nH
values). This effect ofPMA was mimicked by 1 ,M f3PDD but
not by aPDD (data not shown).
Since phorbol esters activate protein kinase C, we hypoth-
esized that phorbol esters uncouple a, receptors from cellular
metabolic events by covalent phosphorylation of the a,-
receptor protein. To test this hypothesis, an affinity chro-
matography procedure for the purification of the solubilized
a1 receptor was developed. After disruption of DDT1 MF-2
cells and preparation of receptor-rich membrane fragments
(0.8 pmol/mg), a, receptors were solubilized with 1%
digitonin with a yield of -30% (2.8 pmol/mg). Soluble a,
receptors were purified by affinity chromatography on the
a,-receptor affinity resin Affi-Gel-A55414. As seen in Fig. 3,
passage of a solubilized preparation over Affi-Gel-A55414
followed by a high-salt buffer wash resulted in -40% reten-
tion of the receptors. Approximately 70% of the adsorbed
receptors were biospecifically eluted by 200 AM phento-
lamine, resulting in an increase in the specific activity of
a,-receptor binding of -300-fold. The binding of 125I-HEAT
to the purified a1-receptor preparations displayed appropri-
ate a, pharmacological specificity (data not shown). As seen
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FIG. 2. Characteristics of a1-adrenergic receptor binding in
control (o) and PMA-treated (o) DDT, MF-2 cells. (Upper) Satura-
tion binding isotherm of 1251I-HEAT. (Lower) Competition of NE for
1251-HEAT binding. The cells were treated with (o) or without (o) 100
nM PMA for 10 min. (Upper) The results shown are typical of three
experiments with each assay performed in triplicate. The computer-
drawn curves represent the best fit to the experimental data (35). The
Kd values are 96 and 78 pM and the Bmax values are 94 and 85 fmol
per 106 cells in control and PMA-treated cells, respectively. (Lower)
Binding assays were performed by using 100-200 pM 1251I-HEAT.
The results are the average of three experiments with each assay
performed in triplicate and are normalized to percentage of maximal
specific binding, which represents 45 ± 6 and 43 ± 4 fmol per 106 cells
(mean ± SEM; n = 3) in control and PMA-treated cells, respectively.
The computer-drawn curves represent the best fit to the experimental
data (35). The EC" values (mean ± SEM; n = 3) are 36 ± 11 ,uM and
60 + 11 ,uM (P < 0.05) and the slope factor (nH) values are 0.45 +
0.05 and 0.63 ± 0.07 (P < 0.01) in control and PMA-treated cells,
respectively.
in Fig. 3 Inset, the major a1-receptor peptide labeled by
[1251]APDQ in the purified preparations was of Mr 80,000.
Fig. 4A shows the results when the a1 receptor was purified
by affinity chromatography from 32P-labeled cells pretreated
or not pretreated with active phorbol esters and such prep-
arations were subjected to NaDodSO4/PAGE. In the ab-
sence of phorbol esters (control), purification yielded a
phosphorylated peptide OfMr 80,000. Exposure of cells to 100
nM PMA resulted in an increase in the 32p content of the M,
80,000 peptide. The active 8PDD, but not the inactive aPDD,
at 500 nM also increased the 32p content of the same peptide.
Fig. 4B shows the electrophoretic pattern of the a1-receptor
photoaffinity labeled in purified DDT, MF-2 plasma mem-
branes with the a1-receptor probe [1251]APDQ in the absence
(control) and presence of 1 ,uM prazosin. Clearly, the majom
specific peptide labeled by [1251]APDQ comigrated with the
0
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FIG. 3. Affinity chromatography of digitonin-solubilized a, re-
ceptors from purified DDT1 MF-2 cell membranes on Affi-Gel-
A55414. The results are the average (mean ± SEM) of nine
experiments. The specific activity of the starting material was in
general 2.8 pmol/mg of protein, as determined from specific
l25i-HEAT binding and the amido schwartz protein assay. (Inset) An
example of a NaDodSO4/PAGE pattern of the phentolamine eluate
photoaffinity labeled with [125I]APDQ. Arrows on the left indicate
molecular weights (shown as Mr x 10-3) of known proteins used as
standards. Arrows on the right indicate the major a,-receptor
peptides. The upper part of the figure shows the chemical structure
of the affinity resin.
major phosphorylated peptide purified by the a1-receptor-
specific affinity chromatography. Interestingly, the minor
phosphorylated peptide at Mr = 35,000-40,000 comigrated
with the major proteolytic product of the a, receptor in these
membranes. The phorbol ester-promoted phosphorylation of
the Mr 80,00Q a,-receptor peptide resulted in an increase in
the 32p content ofthe receptorfrom 1.2 + 0.2 to 3.6 0.1 mol
of 32p per mol of a, receptor (mean SEM; n = 4). The
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FIG. 5. Time course of PMA-promoted increase in a1-adrenergic
receptor (a1-AR) 32P labeling and attenuation of NE-stimulated
PtdOH 32P labeling in DDT1 MF-2 cells. Data regarding the 32p
labeling of the a, receptor were obtained by procedures described in
the legend to Fig. 4. (Inset) An example of the NaDodSO4/PAGE
autoradiogram of a 32P-labeling time course that was used to localize
the M, 80,000 a,-receptor peptide and quantify its 32p content. The
M, 67,000 protein standard is indicated. Data points are the average
of at least two determinations with the PtdOH 32p labeling done in
triplicate.
recovery of receptor activity was similar for control and
PMA-treated cells.
Fig. 5 shows the percent increase in the 32p content of the
Mr 80,000 receptor peptide and the attenuation of NE-
stimulated PtdOH 32p labeling as a function of the time of
PMA treatment. The time courses of the two events closely
paralleled each other, with the half-maximal effect occurring
within 2 min and the maximal effect becoming evident after
=10 min.
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FIG. 4. Effect of phorbol esters on the phosphorylation of the
a,-adrenergic receptor peptides of DDT, MF-2 cells. (A)
NaDodSO4/PAGE of3P-labeled receptor peptides from DDT, MF-2
cells before and after phorbol ester treatment. For 32p labeling the
cells were preinculbated with 32p; for 60 min prior to incubation with
phorbol esters for 15 min. The amount of receptor loaded on each gel
lane was 0.7 pmol. (B) NaDodSO4/PAGE of [1211]APDQ-labeled a,
receptor. Purified DDT, MF-2 cell membranes were incubated with["2I]APDQ in the absence (control) or presence of 1 AuM prazosin and
were processed. Molecular weights of protein standards are shown
as M, x 10-3. The experiment shown was performed twice with
similar results.
DISCUSSION
Treatment of DDT1 MF-2 smooth muscle cells with tumor-
promoting phorbol esters leads to a striking and rapid
alteration of a,-receptor function, as evidenced by the
decreased NE stimulation of inositol lipid metabolism and a
decrease in the affinity of agonist binding to the a, receptors.
This altered function is closely paralleled by phosphorylation
of the a1-adrenergic receptor protein. The former effect is
consistent with a recent report that phorbol ester treatment
leads to inhibition of a1-receptor-mediated stimulation of
hepatic glycogen metabolism (39).
The mechanisms by which phosphorylation of the a1-
receptor protein leads to its uncoupling from polyphospho-
inositide metabolism and the agonist-specific changes in
binding affinity are unclear. This may be due to critical
conformational changes induced in the receptor, which
change its interaction with its effector system. Another
possibility might be the triggering of internalization or se-
questration of the receptor protein away from its normal
plasma membrane location. Although direct ligand binding
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with '25I-HEAT showed no decrease in the number of
receptors in intact cells, it is possible that this hydrophobic
ligand penetrates the cell membrane and is able to bind to
both surface and sequestered receptors. By contrast, the
hydrophilic agonist may be unable to gain access to seques-
tered receptors, and, hence, its binding affinity in such whole
cell assays might be diminished. Just such a mechanism has
been demonstrated recently for the adenylate cyclase-cou-
pled f3-adrenergic receptors (40). The choice between these
two possibilities will require further experimentation. Protein
kinase C-mediated phosphorylation of the receptor for trans-
ferrin appears to trigger its internalization, albeit perhaps for
very different reasons (41).
There is an obvious analogy in the actions of phorbol esters
on a,- and f3-adrenergic receptors, although these receptors
are coupled to different effector systems (PtdIns turnover
versus adenylate cyclase). In each case the phosphorylated
receptor appears to be functionally uncoupled from its
biological effector system (27, 28). However, for a, receptors
the protein kinase C is presumably stimulated physiologically
as a result of diacylglycerol generated consequent to PtdIns-
P2 hydrolysis. Thus, this pathway represents a potential
route for feedback regulation of a,-receptor actions just as
the cyclic AMP-dependent protein kinase appears to regulate
j3-adrenergic receptors (42, 43). Since numerous other ago-
nists can also activate the inositol phospholipid cycle there
are also many other possible pathways for regulating a,-
receptor function via the action of these agonists. Moreover,
these results raise the possibility that the physiological
function of many receptors coupled to this pathway may be
controlled by protein kinase C-mediated phosphorylation.
Note. After submission of this manuscript, two reports (44, 45)
documented phorbol ester-induced attenuation of an a1-adrenergic
response in hepatocytes.
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